Literature DB >> 12845484

In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.

Katia Vandenbulcke1, Filip De Vos, Fritz Offner, Jan Philippé, Christos Apostolidis, Roger Molinet, Tuomo K Nikula, Klaus Bacher, Virginie de Gelder, Anne Vral, Christophe Lahorte, Hubert Thierens, Rudi A Dierckx, Guido Slegers.   

Abstract

External source radiotherapy and beta radioimmunotherapy (RIT) are effective treatments for lymphoid malignancies. The development of RIT with alpha emitters is attractive because of the high linear energy transfer (LET) and short path length, allowing higher tumour cell kill and lower toxicity to healthy tissues. We assessed the relative biological efficacy (RBE) of alpha RIT (in vitro) compared to external gamma irradiation with respect to induction of apoptosis in B chronic lymphocytic leukaemia (B-CLL) and induction of chromosomal damage in healthy donor B and T lymphocytes. The latter was measured by a micronucleus assay. 213Bi was eluted from a 225Ac generator and conjugated to CD20 antibody (rituximab) with CHX-A"-DTPA as a chelator. B-CLL cells from five patients were cultured for 24 h in RPMI/10% FCS while exposed to 213Bi conjugated to CD20 antibody or after external 60Co gamma irradiation. Binding assays were performed in samples of all patients to calculate the total absorbed dose. Apoptosis was scored by flow cytometric analyses of the cells stained with annexin V-FITC and 7-AAD. Apoptosis was expressed as % excess over spontaneous apoptosis in control. Full dose range experiments demonstrated 213Bi-conjugated CD20 antibody to be more effective than equivalent doses of external gamma irradiation, but showed that similar plateau values were reached at 10 Gy. The RBE for induction of apoptosis in B-CLL was 2 between 1.5 and 7 Gy. The micronucleus yield in lymphocytes of healthy volunteers was measured to assess the late toxicity caused by induction of chromosomal instability. While gamma radiation induced a steady increase in micronucleus yields in B and T cells, the damage induced by 213Bi was more dramatic, with RBE ranging from 5 to 2 between 0.1 Gy and 2 Gy respectively. In contrast to gamma irradiation, 213Bi inhibited mitogen-stimulated mitosis almost completely at 2 Gy. In conclusion, high-LET targeted alpha particle exposure killed B-CLL cells more effectively than did external gamma irradiation at a low dose (RBE=2), while a plateau was reached at a high dose. Long-term toxicity on healthy B and T lymphocytes was systematically higher for the alpha emitter (RBE=5 to 2).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12845484     DOI: 10.1007/s00259-003-1228-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  47 in total

1.  A higher micronucleus yield in B-versus T-cells after low-dose gamma-irradiation is not linked with defective Ku86 protein.

Authors:  A Vral; H Thierens; P Bryant; L De Ridder
Journal:  Int J Radiat Biol       Date:  2001-03       Impact factor: 2.694

2.  Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals.

Authors:  D Ma; M R McDevitt; R D Finn; D A Scheinberg
Journal:  Appl Radiat Isot       Date:  2001-10       Impact factor: 1.513

3.  In vivo 'purging' of residual disease in CLL with Campath-1H.

Authors:  M J Dyer; S M Kelsey; H J Mackay; E Emmett; P Thornton; G Hale; H Waldmann; A C Newland; D Catovsky
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

Review 4.  Radioimmunotherapy with alpha-emitting nuclides.

Authors:  M R McDevitt; G Sgouros; R D Finn; J L Humm; J G Jurcic; S M Larson; D A Scheinberg
Journal:  Eur J Nucl Med       Date:  1998-09

5.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

Authors:  T K Nikula; M R McDevitt; R D Finn; C Wu; R W Kozak; K Garmestani; M W Brechbiel; M J Curcio; C G Pippin; L Tiffany-Jones; M W Geerlings; C Apostolidis; R Molinet; M W Geerlings; O A Gansow; D A Scheinberg
Journal:  J Nucl Med       Date:  1999-01       Impact factor: 10.057

6.  Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma.

Authors:  O Couturier; A Faivre-Chauvet; I V Filippovich; P Thédrez; C Saï-Maurel; M Bardiès; A K Mishra; M Gauvrit; G Blain; C Apostolidis; R Molinet; J C Abbe; R Bataille; J Wijdenes; J F Chatal; M Chérel
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

Review 7.  Immunotherapy of Non-Hodgkin's lymphomas.

Authors:  O W Press; J P Leonard; B Coiffier; R Levy; J Timmerman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2001

8.  High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.

Authors:  T M Behr; M Béhé; M G Stabin; E Wehrmann; C Apostolidis; R Molinet; F Strutz; A Fayyazi; E Wieland; S Gratz; L Koch; D M Goldenberg; W Becker
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

9.  Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation.

Authors:  E Aurlien; Y Kvinnsland; R H Larsen; Ø S Bruland
Journal:  Int J Radiat Biol       Date:  2002-02       Impact factor: 2.694

10.  Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia.

Authors:  A Osterborg; A S Fassas; A Anagnostopoulos; M J Dyer; D Catovsky; H Mellstedt
Journal:  Br J Haematol       Date:  1996-04       Impact factor: 6.998

View more
  7 in total

Review 1.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Authors:  C Andrew Boswell; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2007-06-08       Impact factor: 2.408

2.  mFISH analysis of chromosome aberrations in workers occupationally exposed to mixed radiation.

Authors:  Natalia V Sotnik; Sergey V Osovets; Harry Scherthan; Tamara V Azizova
Journal:  Radiat Environ Biophys       Date:  2014-04-09       Impact factor: 1.925

3.  Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.

Authors:  Christof Seidl; Hedwig Schröck; Sabine Seidenschwang; Roswitha Beck; Ernst Schmid; Michael Abend; Karl-Friedrich Becker; Christos Apostolidis; Tuomo K Nikula; Elisabeth Kremmer; Markus Schwaiger; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

Review 4.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

Review 5.  The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.

Authors:  Evan D Read; Peter Eu; Peter J Little; Terrence J Piva
Journal:  Target Oncol       Date:  2014-05-29       Impact factor: 4.493

6.  H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu.

Authors:  Gwendolyn A Bailey; Eric W Price; Brian M Zeglis; Cara L Ferreira; Eszter Boros; Michael J Lacasse; Brian O Patrick; Jason S Lewis; Michael J Adam; Chris Orvig
Journal:  Inorg Chem       Date:  2012-10-29       Impact factor: 5.165

7.  Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells.

Authors:  Mareike Roscher; Inis Hormann; Oliver Leib; Sebastian Marx; Josue Moreno; Erich Miltner; Claudia Friesen
Journal:  Oncotarget       Date:  2013-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.